Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Oncternal Therapeutics Inc (ONCT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow GTX Inc's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
8.3800 +0.1700    +2.07%
27/04 - Closed. Currency in USD ( Disclaimer )
  • Volume: 1,435
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 8.0000 - 8.3800
Type:  Equity
Market:  United States
GTX Inc 8.3800 +0.1700 +2.07%

Oncternal Therapeutics Inc Company Profile

 
Get an in-depth profile of Oncternal Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

29

Equity Type

ORD

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Contact Information

Address 12230 El Camino Real Suite 230
San Diego, 92130
United States
Phone 858 434 1113
Fax 858 408 3010

Top Executives

Name Age Since Title
David F. Hale 75 2019 Independent Chairman of the Board
Daniel L. Kisner 77 2019 Independent Director
Thomas Kipps - - Scientific Advisor
Robert James Wills 70 2019 Non-Independent Director
Xin Nakanishi 62 2019 Independent Director
Gunnar F. Kaufmann 47 2019 Prostate Cancer & Cell Therapy Scientific Advisory Board Member
Charles P. Theuer 60 2019 Independent Director
James B. Breitmeyer 70 2019 President, CEO & Director
Michael G. Carter 86 2006 Independent Director
William R. LaRue 73 2019 Independent Director
Angela Shen - 2021 Cell Therapy Scientific Advisory Board Member
Jill M. DeSimone 68 2023 Independent Director
Rosemary Mazanet 68 2021 Independent Director
Sadik Kassim 43 2021 Cell Therapy Scientific Advisory Board Member
Michael Wang - 2021 Cell Therapy Scientific Advisory Board Member
Johann De Bono - 2023 Prostate Cancer Scientific Advisory Board Member
Marcela V. Maus 47 2021 Cell Therapy Scientific Advisory Board Member
Evan Ya-Wen Yu - 2023 Prostate Cancer Scientific Advisory Board Member
Matthew R. Smith - 2023 Prostate Cancer Scientific Advisory Board Member
Howard R. Soule - 2023 Prostate Cancer Scientific Advisory Board Member
Scott Dehm - 2023 Prostate Cancer Scientific Advisory Board Member
Ramesh Narayanan - 2023 Scientific Advisors
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ONCT Comments

Write your thoughts about Oncternal Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email